deltatrials
No Longer Available EXPANDED_ACCESS NCT04289155

Individual Patient Compassionate Use of GX-I7

Sponsor: Genexine, Inc.

Interventions GX-I7
Updated 6 times since 2020 Last updated: Mar 2, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Advanced Cancer and Glioblastoma, this trial is ongoing. The trial is conducted by Genexine, Inc. and has accumulated 6 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshotAvailable~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotAvailable~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotNo Longer Available~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotNo Longer Available~Sep 2025 – present · 10 months · monthly snapshotNo Longer Available

Change History

6 versions recorded
  1. Sep 2025 — Present [monthly]

    No Longer Available

  2. Sep 2024 — Sep 2025 [monthly]

    No Longer Available

  3. Jul 2024 — Sep 2024 [monthly]

    No Longer Available

  4. Apr 2022 — Jul 2024 [monthly]

    No Longer Available

    Status: AvailableNo Longer Available

  5. Jan 2021 — Apr 2022 [monthly]

    Available

Show 1 earlier version
  1. Mar 2020 — Jan 2021 [monthly]

    Available

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genexine, Inc.
Data source: Genexine, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations